Tamoxifen — No Longer a Golden Standard for Adjuvant Therapy in the Treatment of Premenopausal Patients With Hormone-Sensitive Breast Cancer

Nowotwory - Poland
doi 10.5603/njo.2016.0073
Full Text
Abstract

Available in full text

Date
Authors
Publisher

VM Media SP. zo.o VM Group SK

Related search

Adjuvant Endocrine Therapy in Premenopausal Patients

Breast Care
SurgeryOncology
2008English

Low P27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy

Clinical Cancer Research
Cancer ResearchOncology
2009English

Mammographic Density Reduction Is a Prognostic Marker of Response to Adjuvant Tamoxifen Therapy in Postmenopausal Patients With Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Adjuvant Therapy After Preoperative Treatment for Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2009English

Adjuvant Tamoxifen – Longer Against Shorter (ATLAS)

Breast Cancer Online
2006English

The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2003English

Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment

Clinical Drug Investigation
MedicinePharmacology
2017English

MiR-4653-3p and Its Target Gene FRS2 Are Prognostic Biomarkers for Hormone Receptor Positive Breast Cancer Patients Receiving Tamoxifen as Adjuvant Endocrine Therapy

Oncotarget
Oncology
2016English

Cost-Effectiveness of Anastrozole, in Comparison With Tamoxifen, in the Adjuvant Treatment of Early Breast Cancer in Brazil

Revista da Associacao Medica Brasileira
Medicine
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy